Epsiprantel, a new tapeworm remedy. Preliminary efficacy studies in dogs and cats.
The anthelmintic potential of epsiprantel, 2-(cyclohexylcarbonyl)-4-oxo-1,2,3,4,6,7,8,12b-octahydropyrazin [2,1-a] [2]benzapine, was revealed using the tapeworms Dipylidium caninum and Taenia taeniaeformis in the cat, and Taenia pisiformis and T. hydatigena in the dog. Subsequent controlled tests in cats demonstrated oral efficacy of 100% against D. caninum with a single dose of 2.5 mg/kg. Although consistently 100% effective against T. taeniaeformis at 5 mg/kg, a single worm was found in one cat treated at 7.5 mg/kg. In experimental infections of Taenia pisiformis in dogs, 100% activity was achieved from a single oral dose of 1 mg/kg. No adverse reaction or drug-associated toxicity were observed at dose levels used.
Manger
B R
BR
Brewer
M D
MD
D000284:Administration, Oral; D000818:Animals; D000923:Anticestodal Agents / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D002589:Cestoda / Q000187:drug effects; D002590:Cestode Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005243:Feces / Q000469:parasitology; D011223:Praziquantel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013622:Taeniasis / Q000188:drug therapy / Q000662:veterinary
D000923:Anticestodal Agents; C060885:epsiprantel; D011223:Praziquantel